share_log

Hims & Hers Health | 10-Q: Q3 2024 Earnings Report

Hims & Hers Health | 10-Q: Q3 2024 Earnings Report

Hims & Hers Health | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/05 05:20

Moomoo AI 已提取核心訊息

Hims & Hers Health reported exceptional third-quarter results with revenue surging 77% year-over-year to $401.6 million. The company achieved net income of $75.6 million, compared to a net loss of $7.6 million in Q3 2023. Online Revenue grew 79% to $392.6 million, driven by a 44% increase in subscribers to 2.0 million and a 48% rise in Average Order Value to $147.The company demonstrated strong operational execution with gross margin of 79% and Adjusted EBITDA of $51.1 million, representing a 13% margin. Monthly Online Revenue per Average Subscriber increased 24% to $67, reflecting successful expansion into new offerings and improved product mix. The company also completed the strategic acquisition of MedisourceRx, a 503B compounding facility, for $31 million.Looking ahead, Hims & Hers maintains strong momentum with positive cash flows and a robust balance sheet showing $165.5 million in cash and $88.6 million in investments. The company released $60.8 million of its domestic valuation allowance, reflecting sustained profitability and confidence in future earnings. Management continues to invest in growth initiatives while maintaining operational efficiency.
Hims & Hers Health reported exceptional third-quarter results with revenue surging 77% year-over-year to $401.6 million. The company achieved net income of $75.6 million, compared to a net loss of $7.6 million in Q3 2023. Online Revenue grew 79% to $392.6 million, driven by a 44% increase in subscribers to 2.0 million and a 48% rise in Average Order Value to $147.The company demonstrated strong operational execution with gross margin of 79% and Adjusted EBITDA of $51.1 million, representing a 13% margin. Monthly Online Revenue per Average Subscriber increased 24% to $67, reflecting successful expansion into new offerings and improved product mix. The company also completed the strategic acquisition of MedisourceRx, a 503B compounding facility, for $31 million.Looking ahead, Hims & Hers maintains strong momentum with positive cash flows and a robust balance sheet showing $165.5 million in cash and $88.6 million in investments. The company released $60.8 million of its domestic valuation allowance, reflecting sustained profitability and confidence in future earnings. Management continues to invest in growth initiatives while maintaining operational efficiency.
Hims & HERS Health報告了出色的第三季度業績，營業收入同比增長77%，達到了40160萬美元。公司實現凈利潤7560萬美元，而2023年第三季度淨虧損爲760萬美元。在線營業收入增長了79%，達到39260萬美元，這得益於訂閱用戶數增加44%，達到200萬，以及平均訂單價值增長48%，達到147美元。公司展現了強大的運營執行力，毛利率爲79%，調整後的EBITDA爲5110萬美元，代表了13%的利潤率。每位平均訂閱用戶的每月在線營業收入增長24%，達到了67美元，反映出在新產品提供和產品組合改善方面的成功擴展。公司還完成了對MedisourceRx的戰略收購，這是一家5030億...展開全部
Hims & HERS Health報告了出色的第三季度業績，營業收入同比增長77%，達到了40160萬美元。公司實現凈利潤7560萬美元，而2023年第三季度淨虧損爲760萬美元。在線營業收入增長了79%，達到39260萬美元，這得益於訂閱用戶數增加44%，達到200萬，以及平均訂單價值增長48%，達到147美元。公司展現了強大的運營執行力，毛利率爲79%，調整後的EBITDA爲5110萬美元，代表了13%的利潤率。每位平均訂閱用戶的每月在線營業收入增長24%，達到了67美元，反映出在新產品提供和產品組合改善方面的成功擴展。公司還完成了對MedisourceRx的戰略收購，這是一家5030億的複合製藥設施，收購金額爲3100萬美元。展望未來，Hims & HERS保持強勁勢頭，現金流爲正，穩健的資產負債表顯示現金爲16550萬美元，投資爲8860萬美元。公司釋放了6080萬美元的國內估值準備，反映出持續的盈利能力和對未來收益的信心。管理層繼續投資於增長計劃，同時保持運營效率。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間